Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Truist Securities Maintains Hold on Nevro, Lowers Price Target to $95

Truist Securities maintains Nevro (NYSE:NVRO) with a Hold and lowers the price target from $105 to $95.

December 21, 2021

1 minute read

Truist Securities maintains Nevro (NYSE:NVRO) with a Hold and lowers the price target from $105 to $95.

Exane BNP Paribas Upgrades Trex Co to Neutral, Announces $75 Price Target

Today, 8:22 AM

Exane BNP Paribas analyst Yves Bromehead upgrades Trex Co (NYSE:TREX) from Underperform to Neutral and announces $75 price target.

Today, 8:22 AM

Within the last quarter, Credo Technology Group (NASDAQ:CRDO) has observed the following analyst ratings:

Today, 8:22 AM

Wells Fargo analyst Jared Shaw maintains Triumph Bancorp (NASDAQ:TBK) with a Equal-Weight and raises the price target from $90 to $107.

Today, 8:22 AM

Saol Therapeutics, a company researching new treatments for rare diseases, is pleased to announce a collaboration with GeneDx, Inc.